A global perspective on management of bacterial infections in pregnancy: a systematic review of international guidelines

Michal Koucký, Rasha Kamel, Lucie Vistejnová, Vladimír Kalis, and Khaled M. Ismail

ABSTRACT

Introduction: Maternal sepsis is a leading cause of maternal and neonatal mortality. Despite the availability of management protocols, there is disparity in case fatality rates for pregnancy-related sepsis compared to other maternity-related complications. The main aim of this systematic review was to assess concordance between international evidence-based guidelines for the prevention and management of childbirth-related bacterial infections.

Material and methods: The PRISMA statement was followed during the conduct and reporting of this review. PubMed was searched electronically from 2009 to November 2019 for clinical guidelines covering the topic of childbirth-related infections and specific searches for relevant guidelines on the websites of the top five international professional bodies most commonly identified by our searches. We did not apply any language restrictions. Guidelines were included if they provided any information about the prevention or management of childbirth-related bacterial infections irrespective of whether the guideline stated a recommendation or not. Two independent reviewers undertook study selection, decisions about inclusion of selected guidelines and data extraction. Extracted information was synthesized under the following topics: Asymptomatic bacteriuria; group B streptococcal infection (GBS); preterm premature rupture of membranes (P-PROM); intrauterine infection; procedures; maternal sepsis; miscellaneous.

Concordance was defined as absence of contradictory information between the different guidelines with regards to a specific topic, subtopic or recommendation. Quality of included guidelines was assessed against the AGREE II guideline reporting domains.

Results: A total of 43 guidelines were selected of which 11 were excluded leaving 32 guidelines that fulfilled our inclusion criteria. None of the guidelines fulfilled all the quality assessment domains and 11 (34%) of the guidelines satisfied 1–2 of domains only. Two guidelines covered the topic of asymptomatic bacteriuria, nine for GBS, five for P-PROM and three covered each of intra-amniotic infections maternal sepsis, obstetric procedures and interventions topics. The remaining guidelines covered miscellaneous topics.

Conclusions: There was concordance between guidelines with regards to several aspects in the prophylaxis and treatment of bacteriological infections in pregnancy. Nevertheless, there were several areas of discordance, some of which reached the extent of contradictory information as in the case of antenatal screening for GBS.

Introduction

Pregnancy and childbirth are associated with several physiological changes, both immunological and mechanical, that increase the susceptibility of the mother and baby to infection. Moreover, there are several conditions associated with pregnancy and childbirth that can act as the primary focus for such an infection like Group B streptococcal (GBS) colonization, Premature rupture of membranes (PROM) or urinary tract and wound infections. Childbirth-related infections have been associated with several problems at the long term, including, chronic pelvic pain, subfertility, ectopic pregnancy and consequences of defective mother-child bonding. Pregnancy-related infections
are also one of the leading causes of maternal and neonatal death globally [1–4]. The WHO Global Maternal Sepsis Study (GLOSS) Research Group has recently reported that Infection-related maternal deaths contributed to more than half of the intra-hospital deaths identified during their study period [5]. Although the prevalence of sepsis-related maternal mortality is much higher in low and middle-income countries (LMICs), sepsis in pregnancy is still one of the most important causes of maternal death in the developed world as well [6].

There is disparity in case fatality rates for pregnancy-related sepsis compared to other maternity-related complications. Despite the availability of management protocols, coverage of evidence-based interventions for preventing and treating maternal infectious morbidities is generally suboptimal and varies largely within and across countries. Systematically developed clinical practice guidelines are the foundation based on which healthcare providers plan their management, patients make their choices and regulators set their standards [7]. Given the finite resources from which guidelines can be developed, the standardized methodology for developing them and the clinical importance of perinatal sepsis; one would expect consistency between different evidence-based guidelines covering this topic. Therefore, we hypothesized that there would be no discordance in recommendations between evidence-based guidelines for the prevention and management of childbirth-related bacterial infections developed by different authorities and the objective of this systematic review was to test this hypothesis.

Methods

Search strategy and guideline selection

The PRISMA statement and checklist were followed during the conduct and for the reporting of this review [8]. PubMed was searched electronically from 2009 to November 2019 for clinical guidelines covering the topic of childbirth-related infections. Additionally, we searched the Guidelines International Network (G-I-N) for any relevant guidelines not identified by our PubMed search. We also manually searched the reference lists of selected guidelines to check for possible guidelines not captured by electronic searches. Finally, we performed specific searches for relevant guidelines on the websites of the top five guideline producing obstetrics and gynecology international professional bodies that were most commonly identified by our searches, these were: The American College of Obstetrics and Gynecology (ACOG); Collège National des Gynécologues et Obstétriciens Français (CNGOF); The Royal Australian and New Zealand College of Obstetricians and Gynecologists (RANZCOG); The Royal College of Obstetricians and Gynecologists (RCOG) and The Society of Obstetricians and Gynecologists of Canada (SOGC) (Supplementary material).

Data extraction & synthesis

Two independent reviewers (KI and MK) extracted data from selected guidelines and any discrepancy was sorted by discussion with a third reviewer (VK). Extracted information was logged in an excel spreadsheet and synthesized under the following topics: Asymptomatic bacteriuria; Group B Streptococcal infection (GBS); Preterm Premature rupture of membranes (P-PROM); Intrauterine infection/Chorioamnionitis; Procedures; Maternal sepsis; Miscellaneous. Concordance was defined as absence of contradictory information between the different guidelines with regards to a specific topic, subtopic or recommendation.

Assessment of risk of bias

A bespoke checklist based on the AGREE II checklist domains for guideline reporting was used for assessing risk of bias and quality of included guidelines [9] (Supplementary material).

Results

Guideline selection, guideline characteristics and risk of bias

A total of 43 guidelines were selected of which 11 were excluded leaving 32 guidelines that fulfilled our inclusion criteria (Figure 1, Table 1 and Supplementary material).

Synthesis of results

We analyzed the results under the following clinical categories:

Asymptomatic bacteriuria

Two guidelines, produced on behalf of the United States Preventive Task Force (USPTF) [10] and SOGC [11] discussed this topic and there was concordance between their recommendations (Tables 2 and 3).
**Group B streptococcal infection (GBS)**

Nine guidelines discussed antenatal screening for GBS and/or its intrapartum antibiotic prophylaxis (Tables 1 and 2). These guidelines were produced on behalf of RANZCOG [12], the Canadian Task Force on Preventive Health Care (CTFPHC) [13], SOGC [11], Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)/Sociedad Española de Medicina Familiar y Comunitaria (SEMFYC)/Sociedad Española de Ginecología y Obstetricia (SEGO)/Sociedad Española de Neonatología (SEN)/Sociedad Española de Quimioterapia (SEQ) [14], New Zealand Medical Association (NZMA) [15], American Academy of Pediatrics (AAP) [16], ACOG [17], RCOG [18] and the World Health Organization (WHO) [19].

There was lack of concordance regarding GBS screening policy between the different guidelines. However, there was agreement between the different guidelines that the optimal method of screening. Although there was agreement amongst the guidelines with regards to the use of IV penicillin, there were still some variations in the management protocol (Tables 2 and 3).

**Preterm premature rupture of membranes (P-PROM)**

This topic was covered in 5 guidelines, 2 linked guidelines produced on behalf of CNGOF [20,21] and one produced by each of SOGC [22], ACOG [23] and the RCOG [24]. All the guidelines recommended antibiotic prophylaxis if the woman was not in labor. However there were some discrepancies in the gestational age at which antibiotics should be considered, the recommended gestational age for neuro-protection and management of pregnancies complicated by P-PROM who are GBS positive (Tables 2 and 3).

**Intra-amniotic infections/clinical chorioamnionitis**

Three guidelines (ACOG [25], CNGOF [26] & WHO [19]) covered this topic and there was concordance between the guidelines regarding starting combination antibiotic therapy immediately and maintaining it throughout labor. The guidelines recognized the weakness of evidence to make strong recommendations regarding the duration for which antibiotics should be continued for after delivery (Tables 2 and 3).

**Maternal sepsis**

Our search identified 3 guidelines for the management of maternal sepsis produced on behalf of the Society for Maternal-Fetal Medicine (SMFM)/ACOG [27], RCOG [28] and the Society of Obstetric Medicine Australia and New Zealand (SOMANZ) [29]. Recommendations for investigations, fluid and antibiotic management were fairly consistent between the three guidelines but there were variations between guidelines with regards to criteria for diagnosing maternal sepsis. (Tables 2 and 3).

We identified a guideline produced on behalf of the British Infection Association [30] specific to the prevention and control of group A streptococcal (GAS) infection in acute healthcare and maternity settings in the UK. This is a detailed guideline addressing practical issues for the care of patients with GAS, their families and healthcare workers involved in their care and recommended antibiotic regimens for this infection.
| Reference | Region / Country | Year | Organization | Title | Topic |
|-----------|------------------|------|--------------|-------|-------|
| 10        | USA              | 2019 | USPSTF       | Screening for Asymptomatic Bacteriuria in Adults | Asymptomatic bacteriuria |
|           |                  |      |              | US Preventive Services Task Force Recommendation Statement | |
| 11        | Canada           | 2018 | SOGC         | No. 276-Management of Group B Streptococcal Bacteriuria in Pregnancy | Asymptomatic bacteriuria |
| 12        | Australia / New Zealand | 2019 | RANZCOG     | Maternal Group B Streptococcus in pregnancy: Screening and management | GBS / GBS |
| 13        | Canada           | 2018 | CTFPHC       | The Prevention of Early-Onset Neonatal Group B Streptococcal Disease | GBS |
| 14        | Spain            | 2012 | SEIMC/SEMFYC/SEGO/SEN/SEQ | Prevención de la infección perinatal por estreptococo del grupo B. Recomendaciones españolas revisadas 2012 | GBS |
| 15        | New Zealand      | 2014 | NZMA         | The prevention of early-onset neonatal group B streptococcus infection: New Zealand Consensus Guidelines 2014. | GBS |
| 16        | USA              | 2011 | AAP          | Policy Statement—Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) Disease | GBS |
| 17        | USA              | 2019 | ACOG         | Prevention of Early-Onset Group B Streptococcal Disease in Newborns. ACOG Committee opinion No. 782 | GBS |
| 18        | UK               | 2017 | RCOG         | Prevention of Early-onset Neonatal Group B Streptococcal Disease | GBS |
| 19        | Global           | 2015 | WHO          | WHO recommendations for prevention and treatment of maternal peripartum infections | GBS / Intra-amniotic infection /
|           |                  |      |              | Procedures | |
| 20        | France           | 2018 | CNGOF        | Antenatal management in case of preterm premature rupture of membranes before fetal viability: CNGOF Preterm Premature Rupture of Membranes Guidelines | P-PROM |
| 21        | France           | 2018 | CNGOF        | Preterm premature rupture of membranes: CNGOF Guidelines for clinical practice — Short version | P-PROM |
| 22        | Canada           | 2017 | SOGC         | No. 233-Antibiotic Therapy in Preterm Premature Rupture of the Membranes | P-PROM |
| 23        | USA              | 2016 | ACOG         | ACOG Practice bulletin 172: Premature Rupture of Membranes | P-PROM |
| 24        | UK               | 2019 | RCOG         | Care of Women Presenting with Suspected Preterm Premabour Rupture of Membranes from 24 + 0 Weeks of Gestation | P-PROM |
| 25        | USA              | 2017 | ACOG         | Intrapartum Management of Intraamniotic Infection | Intra-amniotic infection |
| 26        | France           | 2018 | CNGOF        | Diagnosis and management of intra-uterine infection: CNGOF Preterm Premature Rupture of Membranes Guidelines | Intra-amniotic infection |
| 27        | USA              | 2019 | SMFM/ACOG    | SMFM Consult Series #47: Sepsis during pregnancy and the puerperium | Maternal sepsis |
| 28        | UK               | 2012 | RCOG         | Bacterial Sepsis in Pregnancy | Maternal sepsis |
| 29        | Australia & New Zealand | 2017 | SOMANZ      | SOMANZ guidelines for the investigation and management sepsis in pregnancy | Maternal sepsis |
| 30        | UK               | 2012 | British Infection Association | Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK | Maternal sepsis |
| 31        | USA              | 2018 | ACOG         | Use of Prophylactic Antibiotics in Labor and Delivery | Procedures |
| 32        | Canada           | 2017 | SOGC         | No. 247-Antibiotic Prophylaxis in Obstetric Procedures | Procedures |
| 33        | USA              | 2013 | ACOI         | Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012 | Miscellaneous |
| 34        | USA              | 2017 | ACOG         | Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy Tetanus, Diphtheria, and Pertussis Vaccination | Miscellaneous |
| 35        | USA              | 2014 | ACOG         | Committee Opinion No. 614: Management of Pregnant Women With Presumptive Exposure to Listeria monocytogenes | Miscellaneous |
| 36        | USA              | 2014 | ABM Clinical Protocol #4: Mastitis, Revised March 2014 | Miscellaneous |
| 37        | Canada           | 2015 | SOGC         | Adolescent Pregnancy Guidelines | Miscellaneous |
| 38        | France           | 2019 | CNGOF / SPIF | Postpartum endometritis: CNGOF and SPIF Pelvic Inflammatory Diseases Guidelines | Miscellaneous |
| 39        | Germany          | 2009 | Kommission Qualitats sicherung der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe | Wassergeburt: Infektionsprophylaxe und Kontraindikationen | Miscellaneous |
| 40        | USA              | 2013 | ACOG         | Oral Health Care During Pregnancy and Through the Lifespan | Miscellaneous |
| 41        | Spain            | 2015 | Spanish Association of Pediatrics | Spanish Society for Pediatric Infectious Diseases guidelines on tuberculosis in pregnant women and neonates (ii): Prophylaxis and treatment | Miscellaneous |
Concordance and discordance of recommendations between included guidelines by topic.

| Topic | Concordance | Comments |
|-------|-------------|----------|
| Asymptomatic bacteriuria | Concordance regarding universal screening for asymptomatic bacteriuria in pregnancy using mid-stream urine cultures. Both guidelines recommended treatment for a colony count $\geq 100,000$ colony-forming units per milliliter, using an appropriate antibiotic. Both guidelines highlighted the moderate degree of certainty with regards to the evidence of benefit in support of treatment where the evidence was graded as B-recommendation and II-2A by both guidelines respectively. |
| GBS | Lack of concordance regarding GBS screening policy between the different guidelines. A policy of routine screening of pregnant women between 35-37 weeks was recommended by CTFHC, SOGC, SBMC, SEMFYC/SEGO/SBN/SEQ, AAP and CDC. In contrast, NZMA and the RCOG did not recommend universal bacteriological screening for GBS. The RCOG concluded that there was lack of clear evidence to show that routine testing for GBS would do "more good than harm". Although RANZCOG recommended routine screening between 35-37 weeks, they also stated that a risk-based approach was acceptable. The WHO guideline development group acknowledged the "considerable variations in policies regarding the screening for GBS colonization in pregnant women" and agreed that this recommendation should be implemented in line with local policy. |
| P-PROM | Concordance regarding antibiotic prophylaxis if the woman was not in labor. However there were some discrepancies in the gestational age at which antibiotics should be considered. The SOGC guideline recommended that prophylaxis should be given if $\leq 32$ weeks' gestation and considered above 32 weeks if fetal lung maturity could not be proven and/or delivery is not planned (level I-A). CNGOF used a cut-off of $<37$ weeks for using antibiotic prophylaxis (Level A) while ACOG recommended a cut-off of $<34 = 0$ weeks of gestation. With regards to antibiotic regimens, the RCOG recommended erythromycin for 10 days, CNGOF suggested amoxicillin, 3rd generation cephalosporins, and erythromycin in monotherapy or erythromycin + amoxicillin (professional consensus) for 7 days (grade C), to be discontinued if vaginal cultures are negative, while ACOG recommended a 7-day course of therapy with a combination of intravenous ampicillin and erythromycin followed by oral amoxicillin and erythromycin. The regimen endorsed by SOGC was either ampicillin 2 g IV every 6 h and erythromycin 250 mg IV every 6 h for 48 h followed by amoxicillin 250 mg orally every 8 h and erythromycin 333 mg orally every 8 h for 5 days or erythromycin 250 mg orally every 6 h for 10 days (level I-A). | The JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE |
| Intra-amniotic infection | There were minor variations in the criteria for diagnosing intra-amniotic infections. According to CNGOF: a body temperature $\geq 38.0\, ^\circ$C with no alternative cause identified and at least 2 of the following signs: fetal tachycardia $\geq 160$ bpm for 10 min or longer and uterine pain or purulent cervical discharge (professional consensus). The group also added that the presence of maternal leukocytosis, in the absence of corticosteroids treatment, or increased plasma C-reactive protein should be taken into consideration despite their limited sensitivity and specificity (Evidence Level 3). ACOG used a cut-off of $\geq 39\, ^\circ$C for maternal temperature, on its own or $38.0 - 38.9\, ^\circ$C together with one additional clinical risk factor. The WHO guideline acknowledged the variability and weakness of evidence regarding diagnostic criteria and did not state a recommendation. |
| Maternal sepsis | The SMFM/ACOG guideline recommended the use of the quick sequential organ failure assessment (qSOFA) score for patient evaluation, SOMANZ recommended the obstetrically modified qSOFA for initial assessment then the obstetrically modified SOFA for a more thorough assessment. However, the RCOG advised relying on one or more of the following clinical signs suggestive of sepsis: pyrexia, hypothermia, tachycardia, tachypnea, hypoxia, hypotension, oliguria, impaired consciousness and failure to respond to treatment. Nonetheless, the guideline highlighted that these symptoms might not be present and that they are not necessarily related to the severity. |
| Procedures | Recommendations for or against the use of prophylactic antibiotics in relation to cerclage, episiotomy, cesarean section, OASIs and operative vaginal delivery were fairly concordant. However, there was discrepancy with regards to recommendations about antibiotic prophylaxis and manual removal of the placenta. |
Pregnancy-related procedures
We identified three guidelines that addressed issues related to antibiotic prophylaxis in relation to some obstetric-related procedures (Tables 2 and 3). These were produced on behalf of the WHO [19], ACOG [31] and SOGC [32] and covered the following procedures:

Cerclage - Both ACOG and SOGC did not support the use of prophylactic antibiotics to reduce infectious morbidity following elective or emergency cerclage (SOGC - II-3).

Episiotomy - The WHO did not recommend antibiotic prophylaxis for episiotomy.

Cesarean section - There was consistency between the SOGC, ACOG and WHO with regards to antibiotic prophylaxis for cesarean section. Guidelines recommended that a single dose cephalosporin is given 15–60 min prior to skin incision, SOGC and ACOG recommended an additional dose of antibiotic prophylaxis if an open abdominal procedure is lengthy (>3 h) or estimated blood loss is greater than 1500 ml. (SOGC - Grade III). Moreover, they advised that in patients with morbid obesity (BMI > 35), doubling the antibiotic dose may be considered (Grade III-B). Although ACOG did not recommend routine screening of pregnant women for methicillin-resistant staphylococcus aureus (MRSA), the guideline suggested that consideration might be given to adding a single dose of vancomycin to the recommended antibiotic prophylaxis regimen for women undergoing cesarean delivery and known to have MRSA.

Operative vaginal delivery – The SOGC guideline concluded that the available evidence did not support the use of prophylactic antibiotics to reduce infectious morbidity following operative vaginal delivery (Grade II-1). The WHO made a similar recommendation (conditional recommendation based on very low-quality evidence).

Obstetric anal sphincter injuries (OASIs) – The WHO recommended routine antibiotic prophylaxis for women who sustain OASIs. ACOG considered a single dose of antibiotic at the time of repair is reasonable (Level B). The SOGC guideline stated, “Prophylactic antibiotics may be considered for the reduction of infectious morbidity associated with repair of third and fourth degree perineal injury” (SOGC - Grade I-B).

Manual removal of the placenta (MROP) - There was some discordance between the guidelines regarding this procedure. ACOG and SOGC highlighted that there were not enough data to argue for or against antibiotic prophylaxis at the time of MROP (SOGC – Grade III). While, routine antibiotic prophylaxis was recommended by the WHO for women undergoing the procedure (strong recommendation based on very low-quality evidence).

Miscellaneous
Our search identified some guidelines that covered different topics. Two of these related to Tetanus, Diphtheria, and Pertussis Vaccination produced on behalf of the Advisory Committee on Immunization Practices (ACIP) [33] and ACOG [34] with concordant advice. The rest of the guidelines [35–41] covered a specific type of bacteria, clinical context or generic advice (Table 1).

Discussion
Main findings
Our systematic review has demonstrated concordance between guidelines with regards to several aspects in the prophylaxis and treatment of bacterial infections in pregnancy. Nevertheless, there were several areas of discordance, some of which reached the extent of contradictory information as in the case of antenatal
screening for GBS. Neonatal early onset GBS has been a recognized cause of neonatal morbidity and mortality for a long time [42,43]. The main precipitating factor for neonatal infection is maternal GBS colonization [44]. It is for this reason that several professional bodies in the USA, Spain, Australia and Canada support universal antenatal screening. However, both the NZMA and the RCOG did not support this policy. Importantly, the RCOG based their decision on the UK National Screening Committee’s opinion that there is no clear evidence demonstrating benefits of routine GBS screening, lack of availability of an entirely accurate screening test and that GBS status at 35–37 weeks of gestation does not reflect GBS status at the time of delivery [18]. In stark contrast, AAP reported that the wide adoption of their recommended routine antenatal GBS screening policy resulted in an estimated 80% reduction in early onset GBS [16,45]. This observation was also more recently independently confirmed [46]. Interestingly, the issue of discrepancy within Europe was the driver behind organizing a specific conference in 2013 with experts in neonatology, obstetrics and clinical microbiology with the main aim of facilitating a consensus toward European guidelines for the management of pregnant women in labor and during pregnancy for the prevention of GBS perinatal disease. The key decision issued after the conference is to recommend intrapartum antimicrobial prophylaxis based on a universal intrapartum GBS screening strategy using a rapid real time testing [47].

There was consistency between guidelines in their recommendation of antibiotic prophylaxis in P-PROM however different guidelines suggested different gestational ages for considering such prophylaxis. The discrepancies between guidelines regarding gestational ages for instigating interventions might be perceived as a minor issue. Nonetheless, there will be a significant number of women who will present with P-PROM between 32 and 37 weeks who might have had antibiotic prophylaxis based on one guideline or were denied that, and probably delivered, based on another. This is particularly relevant when considering the burden of morbidity associated with P-PROM where 25% will be complicated by clinical chorioamnionitis and up to 20% will sustain postpartum infection [48,49].

Maternal sepsis is a significant contributor to maternal mortality and considered by WHO as “life threatening” in their newly proposed definition of the condition [6,50]. Therefore, one would expect that there would be consistency in its management. We identified three guidelines only that addressed maternal sepsis. Interestingly, the WHO guideline, although entitled “Prevention and treatment of maternal peripartum infections,” provided no specific criteria for the diagnosis or management of sepsis. Two of the three included guidelines recommended the use of scoring tools for diagnosis; however, the RCOG suggested relying on clinical assessment. There are several tools suggested to screen for and diagnose a critically ill patient. These tools use different variables and thresholds to predict the need for specialized care or poor outcome. It is suggested that these tools are not good for the prediction or risk stratification in relation to maternal sepsis [51,52]. Moreover, there is paucity of information to enable the validation of a standardized set of investigations that can reliably diagnose maternal sepsis [51,52]. It is possible that these are the reasons behind which the RCOG did not recommend the use of a specific diagnostic tool. Indeed, the global maternal sepsis study (GLOSS) was set up with one of its main objectives to develop and validate identification criteria for possible severe maternal infection and maternal sepsis [53]. This issue has been highlighted by the GLOSS group, following their recent study, where they stressed the urgent need to improve early identification of maternal sepsis [5].

There were agreements between several guidelines with regards to the need for antibiotic prophylaxis in relation to several pregnancy related surgical procedures and interventions. Interestingly, there was 100% agreement between the guidelines in not recommending antibiotic prophylaxis during OVD despite recent evidence of its benefit [54]. We appreciate that the development dates of these guidelines predates the availability of this evidence and this information might appear in future guideline updates. However, it also raises the issue of how often should guidelines be updated and whether this should be a continuous ongoing process or not [55]. We identified only one discrepancy in the level of evidence listed for the recommendation. Nonetheless, different professional bodies use different evidence grading systems, which can be a cause of potential confusion to the reader (Supplementary material).

**Comparison with existing literature**

According to the Agency for Healthcare Research and Quality, evidence-based research provides the bases for sound clinical practice guidelines and recommendations. It is possible that variations are a reflection of differences in populations, bacterial prevalence or healthcare delivery systems. Nevertheless, if the research that feeds into
these guidelines comes from one source, one would expect that the recommendations generated would be similar. Our systematic review does not support this notion where several considerable variations in the interpretation of this evidence resulted in heterogeneity between the recommendations of the different guidelines for the same clinical problem. In the presence of strict criteria for the development of an evidence based guideline and, fairly, similar systems for grading the level of evidence, it would be expected that recommendations reflect the actual evidence available at the time rather than the subjective interpretation of the guideline authors. However, Nelson et al. suggest that when the evidence about the effectiveness of an intervention is unclear, the decision to adopt or refute such an intervention relies upon subjective judgments about the quality of the studies in question [56]. In this situation, if there is a perception that the condition poses a relatively high risk, the guideline development group may recommend an intervention despite inadequate evidence [57]. But, Carlsen and Norheim stress that in such circumstances, it is best for guideline developers to be clear about “value judgments” [58]. Although only speculative, this might be the reason for the discrepancies in the recommendations between the guidelines. However, at least, for some of these differences, the issue of value judgment was not clearly stated, in fact, different studies were used to justify the recommended policy as in the case of GBS screening.

**Strengths and limitations**

The main strength of our systematic review lies in the methodology we followed in the initial selection of guidelines, the decision about their inclusion and in extracting data from these guidelines which were all done in duplicates by two independent reviewers. We also followed the AGREE II domains for assessing the quality of included guidelines. However, we are aware that despite our efforts to be inclusive, some guidelines that might have had recommendations related to the prevention and management of bacterial infections in relation to certain aspects of maternity care were not included. This applied to guidelines that are not identified on a PubMed search as in the case of the Nordic Federation of Societies of Obstetrics and Gynecology (NFOG) guidelines. It also applied to recommendations that appeared in the context of a condition specific guideline and would not have been identified by our search strategy. As an example is the RCOG guideline for the management of 3rd and 4th degree perineal tears where the guideline recommends the use of antibiotic prophylaxis [59]. There are probably several other examples that would fit under these categories. Nonetheless, the aim of our systematic review was not to present all the recommendations in relation to maternity-related bacterial infections but rather to assess the degree of concordance in a representative sample of international guidelines and we had to follow a pre-specified search strategy to mitigate the risk of introducing bias into our review.

**Conclusion**

We appreciate that the variations we identified between guidelines do not necessarily translate into variation in care within the country where the guideline was produced by its professional body. However in many other countries clinicians rely on evidence-based guidelines produced by reputable professional societies and colleges. Adoption of different guidelines by different units, or even clinicians, in such countries can result in a high degree of variability in practice. This can have serious patient safety and medico-legal consequences. Therefore we wonder; In a world that is smaller than ever, a population that is more mobile than ever and with the existence of platforms that facilitate communication faster than ever; isn’t it time to have unified international guidelines, at least for something as common as pregnancy?

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

KI and LV are partly funded by project No. CZ.02.1.01/0.0/0.0/16_019/0000787 “Fighting INfectious Diseases - FIND”, awarded by the Ministry of Education, Youth and Sports of the Czech Republic, financed from The European Regional Development Fund. Funders were not involved in the design, analysis or the reporting of this work.

**ORCID**

Khaled M. Ismail http://orcid.org/0000-0001-9449-0706

**Authors’ contributions**

- MK: Study selection, Data extraction, Manuscript editing and revision
- RK: Study selection, Quality assessment, Manuscript editing and revision
- LV: Study selection, Manuscript editing and revision
- VK: Data extraction and synthesis, Manuscript editing and revision
References

[1] Chou D, Tunçalp Ö, Firoz T, et al. Constructing maternal morbidity - towards a standard tool to measure and monitor maternal health beyond mortality. BMC Pregnancy Childbirth. 2016;16:45.

[2] Chan GJ, Lee AC, Baqui AH, et al. Risk of early-onset neonatal infection with maternal infection or colonization: a global systematic review and meta-analysis. Santosham M, editor. PLoS Med. 2013;10(8):e1001502.

[3] Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969–1987.

[4] Lawn JE, Cousens S, Zupan J. 4 Million neonatal deaths: When? Where? Why? Lancet. 2005;365(9462):891–900.

[5] Bonet M, Brizuela V, Abalos E, et al. Frequency and management of maternal infection in health facilities in 52 countries (GLOSS): a 1-week inception cohort study. Lancet Glob Heal. 2020;8(5):e661–e671.

[6] Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Heal. 2014;2(6):e323–e333.

[7] Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical practice guidelines. Directions for a new program. Field MJ, Lohr KN, editors. Washington (DC): National Academies Press; 1990.

[8] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.

[9] Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. J Clin Epidemiol. 2010;63(12):1308–1311.

[10] Owens DK, Davidson KW, Krist AH, et al. Screening for asymptomatic bacteriuria in adults: US preventive services task force recommendation statement. JAMA. 2019;322(12):1188–1194.

[11] Allen VM, Yudin MH. No. 276-Management of Group B streptococcal bacteriuria in pregnancy. J Obstet Gynaecol Canada. 2018;40(2):e186–e187.

[12] The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Maternal Group B Streptococcus in pregnancy: screening and management. R Aust New Zeal Coll Obstet Gynaecol. 2019:1–14.

[13] Money D, Allen VM. No. 298-the prevention of early-onset neonatal group b streptococcal disease. J Obstet Gynaecol Can. 2018;40(8):e665–e674.

[14] Cortés JIA, Domingo AA, Mir LA, et al. Prevención de la infección perinatal por estreptococo del grupo B. Recomendaciones españolas revisadas 2012. Progresos Obstet y Ginecol. 2012;55:337–346.

[15] Darlow B, Campbell N, Austin N, et al. The prevention of early-onset neonatal group B streptococcus infection: New Zealand Consensus Guidelines 2014. N Z Med J. 2015;128(1425):69–76.

[16] Brady MT, Bernstein HH, Byington CL, et al. Policy statement - recommendations for the prevention of perinatal group B streptococcal (GBS) disease. Pediatrics. 2011;128:611–616.

[17] Prevention of Group B streptococcal early-onset disease in newborns: ACOG Committee Opinion Summary, Number 782. Obstet Gynecol. 2019;134:206–210.

[18] Prevention of early-onset neonatal group B streptococcal disease. BJOG. 2017;124:e280–e305.

[19] WHO. WHO recommendations for prevention and treatment of maternal peripartum infections. Geneva: WHO; 2015.

[20] Schmitz T, Sentilhes L, Lorthe E, et al. Rupture prématurée des membranes avant terme : recommandations pour la pratique clinique du CNGOF — Texte court. Gynécologie Obs Fertil Sénologie. 2018;46(12):998–1003.

[21] Azria E. Prise en charge anténatale en cas de rupture prématurée des membranes avant la viabilité foetale. RPC Rupture prématurée des membranes avant terme CNGOF. Gynécologie Obs Fertil Sénologie. 2018;46(12):1076–1088.

[22] Yudin MH, van Schalkwyk J, Van Eyk N. No. 233-antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can. 2017;39(9):e207–e212.

[23] Ehsanipoor R, The American College of obstetricians and gynecologists. Obstet Gynecol. 2016;128: e165–e177.

[24] Thomson AJ, Royal College of Obstetricians and Gynaecologists. Care of women presenting with suspected preterm prelabour rupture of membranes from 24 + 0 weeks of gestation: green-top guideline no. 73. BJOG. 2019;126:e152–e166.

[25] Committee on Obstetric Practice. Committee opinion no. 712: intrapartum management of intraamniotic infection. Obstet Gynecol. 2017;130:e95–e101.

[26] Beucher G, Charlier C, Cazaneave C. [Diagnosis and management of intra-uterine infection: CNGOF Preterm Premature Rupture of Membranes Guidelines] . Gynecol Obstet Fertil Senol. 2018;46(12):1054–1067.

[27] Plante LA, Pacheco LD, Louis JM. SMFM Consult Series #47: sepsis during pregnancy and the puerperium. Am J Obstet Gynecol. 2019;220:B2–B10.

[28] Royal College of Obstetricians and Gynaecologists. Bacterial Sepsis in pregnancy: green top guideline No.64a. R Coll Obstet Gynaecologists. 2012:1–14.

[29] Bowyer L, Robinson HL, Barrett H, et al. SOMANZ guidelines for the investigation and management sepsis in pregnancy. Aust N Z J Obstet Gynaecol. 2017;57(5):540–551.

[30] Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal
infection in acute healthcare and maternity settings in the UK. J Infect. 2012;64(1):1–18.
[31] Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2018;132:e103–e119.
[32] van Schalkwyk J, Van Eyk N. No. 247-antibiotic prophylaxis in obstetric procedures. J Obstet Gynaecol Can. 2017;39(9):e293–e299.
[33] Sawyer M, Liang JL, Messonnier N, et al. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. Morb Mortal Wkly Rep. 2013;62:131–135.
[34] Committee Opinion No. 718 Summary: update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol. 2017;130:668–669.
[35] Management of pregnant women with presumptive exposure to listeria monocytogenes. Obstet Gynecol. 2014;124:1241–1244.
[36] Amir LH, Academy of Breastfeeding Medicine Protocol Committee. ABM Clinical Protocol #4: Mastitis, Revised March 2014. Breastfeed Med. 2014;9(5):239–243.
[37] Fleming N, O’Driscoll T, Becker G, et al. Adolescent pregnancy guidelines. J Obstet Gynaecol Canada. 2015;37(8):740–756.
[38] Faure K, Dessein R, Vanderstichele H, et al. [Postpartum endometritis: CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines]. Gynecol Obstet Fertil Senol. 2019;47(3):442–450.
[39] FüR K, d S, Geburtshilfe G. u. Wassergeburt: Infektionsprophylaxe und Kontraindikationen. Gynakol Geburtshilfliche Rundsch. 2009;49:341–343.
[40] American College of Obstetricians, Committee on Health Care for Underserved Women. Committee Opinion No. 569: oral health care during pregnancy and through the lifespan. Obstet Gynecol. 2013;122:417–422.
[41] Baquero-Artigao F, Mellado Peña MJ, del Rosal Rabes T, et al. [Spanish Society for Pediatric Infectious Diseases guidelines on tuberculosis in pregnant women and neonates (I): epidemiology and diagnosis. Congenital tuberculosis]. An Pediatr (Barc). 2015;83(4):285.e1–285.e8.
[42] Baker CJ. Early onset group B streptococcal disease. J Pediatr. 1978;93(1):124–125.
[43] Baker CJ, Barrett FF, Gordon RC, et al. Suppurative meningitis due to streptococci of lancefield group B: a study of 33 infants. J Pediatr. 1973;82(4):724–729.
[44] Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr. 1973;83(6):919–925.
[45] Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med. 2009;360(25):2626–2636.
[46] Rottenstreich M, Rotem R, Bergman M, et al. Assessment of maternal GBS colonization and early-onset neonatal disease rate for term deliveries: a decade perspective. J Perinat Med. 2019;47(5):528–533.
[47] Di Renzo GC, Melin P, Berardi A, et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Matern Neonatal Med. 2015;28(7):766–782.
[48] Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of the membranes before 28 weeks: conservative management. Am J Obstet Gynecol. 1996;175(3):471–479.
[49] WHO. Statement on maternal sepsis sepsis. WHO; 2017. p. 1–4.
[50] Edwards SE, Grobman WA, Lappen JR, et al. Modified obstetric early warning scoring systems (MOEWS): validating the diagnostic performance for severe sepsis in women with chorioamnionitis. Am J Obstet Gynecol. 2015;212(4):536.e1–536.e8.
[51] Aarvold ABR, Ryan HM, Magee LA, et al. Multiple organ dysfunction score is superior to the obstetric-specific sepsis in obstetrics score in predicting mortality in septic obstetric patients. Crit Care Med. 2017;45:e49–e57.
[52] Bonet M, Souza JP, Abalos E, et al. The global maternal sepsis study and awareness campaign (GLOSS): study protocol. Reprod Health. 2018;15(1):16.
[53] Knight M, Chiocchia V, Partlett C, et al. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet. 2019;393(10189):2395–2403.
[54] Shekelle P, Eccles MP, Grimshaw JM, et al. When should clinical guidelines be updated? BMJ. 2001;323(7305):155–157.
[55] Nelso HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727–737.
[56] Cuervo LG, Clarke M. Balancing benefits and harms in health care. Br Med J. 2003;327(7406):65–66.
[57] Carlens B, Norheim OF. "What lies beneath it all?" - An interview study of GPs’ attitudes to the use of guidelines. BMC Health Serv Res. 2008;8:218.
[58] Fernando R, Sultan A, Freeman R, et al. The management of third- and fourth-degree perineal tears (Green-top guideline no. 29). 2015. p. 1–19.